BioSpace News Archive

OpSens Inc. (“OpSens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, will report financial results for its first quarter of fis

Leading academic health center aims to improve the care experience and reduce physician burnout after a successful pilot found Nuance DAX cuts time spent on clinical documentation by more than half

Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”) , a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today issued a letter to shareholders from it

Forlenza brings over 40 years of experience in leadership roles at BD, a $70B market cap medical technology market leader, and will bring a wealth of knowledge in commercialization, scaling healthcare businesses, and improving patient outcomes

Servier, a global pharmaceutical Group and X-Chem, Inc., a privately held drug discovery company announced today a partnership to identify and develop novel small molecules for the treatment of neurological disorders.

MED-EL USA, a leader in implantable hearing solutions, today announced the launch of the SAMBA 2, a next-generation audio processor for the BONEBRIDGE Bone Conduction System, which includes the recently launched BCI 602. BCI 602 is an active transcutaneous bone conduction implant that leaves skin intact.

Seasoned experts across physics and electronics industries bring experience from Texas Instruments, Los Alamos National Laboratory and Xilinx to guide further growth in R&D, manufacturing and education markets

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of industry veteran Frank Neumann, M.D., Ph.D., as Chief Medical Officer

Biome Analytics, the leading cardiovascular performance company, announces the results of original research published in the Journal of the American Heart Association (JAHA)

Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today raised revenue guidance to over $2 million for the fourth quarter of 2020, a 67% sequential increase over $1.2 million reported for the third quarter of 2020. Arjan Haverhals, President of Milestone Scientific and CEO of Wand Dental Inc., stated, “I am pleased to report